Neurimmune
Tracked across 3 events · 19 articles · First seen Jun 24, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Neurimmune receives up to $425 million in exchange for a portion of its royalty interest, providing funds to advance its R&D pipeline while retaining majority royalty and milestone interests.
Jul 22, 2026 · 7 articles
Business
Impact: Neurimmune co-led the financing and is a strategic partner, having discovered the anti-Nogo-A antibody NG004. Its involvement validates the science and deepens its stake in NovaGo's success.
Jul 20, 2026 · 6 articles
Tech
Impact: Neurimmune is a co-owner of ALS Pharma, contributing to the development of IBM System/4 Pi.
Jun 24, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Neurimmune live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard